On November 7, 2018 Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA) constructs, reported plans to attend two investor conferences and two scientific conferences in November 2018 (Press release, Exicure, NOV 7, 2018, View Source;p=RssLanding&cat=news&id=2375799 [SID1234530970]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exicure will be providing a corporate update November 13th, from 3:30 to 4:10 EST at the Stifel Healthcare Conference at the Lotte New York Palace, New York City. A live audio webcast will be available on the Events & Presentations section of Exicure’s website: www.exicuretx.com. A replay will be available for approximately 30 days. The company will also be attending the Jefferies London Healthcare Conference, November 14-15 at the Waldorf Hilton, London.

On November 9th and 10th the company will be presenting at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) conference at the Walter E. Washington Convention Center; Washington, D.C. Additionally, the company will be presenting at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Molecular Targets and Cancer Therapeutics Symposium November 13-16 at The Convention Centre Dublin; Dublin, Ireland

On November 7, 2018 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, reported that an overview of the company’s business strategy and commercial and development-stage programs will be given at the Jefferies 2018 London Healthcare Conference being held in London (Press release, Spectrum Pharmaceuticals, NOV 7, 2018, http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-corporate-update-jefferies-2 [SID1234530969]). The company presentation is on Wednesday, November 14, 2018, at 3:20 PM GMT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Spectrum’s presentation will be available at www.sppirx.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 7, 2018 Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England (Press release, Zymeworks, NOV 7, 2018, View Source [SID1234530951]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will provide a corporate update at the Stifel Healthcare Conference on Tuesday, November 13, 2018 at 8:00 a.m. ET and at the Jefferies Healthcare Conference on Wednesday, November 14, 2018 at 2:40 p.m. GMT (9:40 a.m. ET).

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at View Source, which will also host a recorded replay available afterwards.

On November 7, 2018 Synlogic, Inc. (Nasdaq: SYBX), reported that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018 (Press release, Synlogic, NOV 7, 2018, View Source [SID1234530949]). The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the call is 2674209. Participants may access the live webcast via a link on the Synlogic website in the Events Calendar of the Investors and Media section